OR WAIT null SECS
The $11.6-billion acquisition strengthens Sanofi's position in hematology and specialty medicines.
On March 8, 2018, Sanofi announced that it has acquired Bioverativ, Biogen’s hemophilia and blood disorders-focused company, for $105 per share in cash.
Initially announced in January 2018, this acquisition strengthens Sanofi's position in hematology and specialty medicines by adding Bioverativ's Eloctate (recombinant fusion protein composed of human immunoglobulin[IG] G1-Fc linked cleavage factor VIII) and Alprolix (recombinant fusion protein composed of IX coagulation factor IX Fc fragment of IgG1) for the treatment of hemophilia A and hemophilia B, respectively, to Sanofi’s hemophilia portfolio. Bioverativ produced $1.17 billion in sales in 2017.
“The addition of Bioverativ provides us with a strong position in the large and growing hemophilia market and expands our presence in specialty care,” said Olivier Brandicourt, CEOß at Sanofi, in a company press release. “Through a series of three strategic transactions-the addition of Bioverativ, our planned acquisition of Ablynx and our agreement for fitusiran-we are well on our way to creating a leading franchise in the field of rare blood disorders.”